Healthcare Services Hong Kong

Hong Kong Antimicrobial Susceptibility Testing Market Analysis, 2024–2034

Updated Reviewed by Chandani Patel

Hong Kong Antimicrobial Susceptibility Testing (AST) Market Industry Trends and Forecast to 2034: Segmented by (By Test Type, Application, End Users, Product) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Buy the full report

Report snapshot

Hong Kong Antimicrobial Susceptibility Testing Market Analysis at a glance
Market size, 2025Researched figures come with the full report
Forecast, 2034Researched figures come with the full report
Growth (CAGR), 2025–2034Researched figures come with the full report
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsTest type, application, end user, product and method (see all)
Key playersThermo Fisher Scientific Inc., Alifax S.r.l., Creative Diagnostics, Resistell AG, Danaher Corporation and 13 more (see all)
Active clinical trials2 in Hong KongSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Hong Kong. Retrieved 9 Nov 2026.
FormatsPDF, PPTX, XLSX

The Hong Kong Antimicrobial Susceptibility Testing (AST) Market Analysis Executive Summary

Antimicrobial susceptibility testing (AST) is a laboratory procedure which is used to determine which antimicrobial impedes the growth of bacteria, fungi, and other microorganism causing a specific infection. Once the microorganisms have been recovered in a specimen culture, susceptibility testing is carried out on the bacteria and fungi responsible for the infection.

Antibacterial medications are crucial for preventing infectious infections; however drug resistance has developed as a result of drug abuse and overuse. Controlling the spread of infectious diseases becomes challenging when dangerous bacteria are not identified in a timely manner. This is increasing the pressure on the major businesses to produce test kits that yield precise and useful results so that patients can be treated more effectively.

Testing is done to see if microorganisms have become resistant to any particular antibiotic and to assess the possible efficacy of antibiotics on germs. Healthcare practitioners can choose the medication that is most likely to be helpful in treating that specific infection with the aid of the test findings, which can provide access to improved clinical diagnoses.

Market Dynamics for Antimicrobial Susceptibility Testing Market in Hong Kong

Market Growth Drivers Analysis

Over the projected market, it is anticipated that major companies will increasingly employ inorganic development tactics, like product launches, to propel market expansion. The medical technology company Sysmex Corporation, for example, recently announced the launch of a point-of-care testing system in Europe that can identify an individual's resistance to antibiotics in as little as half an hour. Urine samples from patients suspected of having urinary tract infections (UTIs) are used by the system to detect the presence or absence of bacteria and evaluate the efficacy of antibiotics. The device performs antimicrobial susceptibility testing (AST) using a special and proprietary microfluidic technique. Comparing the multiple days needed for conventional AST to as little as 30 minutes from the beginning of measurement, it shows a significant reduction.

The Hong Kong Antimicrobial Susceptibility Testing (AST) market is expanding as a result of this move away from traditional techniques and toward cutting-edge diagnostic platforms. Simple, easy-to-use systems that are appropriate for both point-of-care and routine testing in core laboratories are being introduced by diagnostic businesses on a regular basis. The AST uptake is being further increased by the development of platforms that integrate the sample-to-result workflow and yield findings that are equivalent to reference procedures. Therefore, as technology advances, it plays a significant role in enhancing antibiotic stewardship by addressing some of the shortcomings of current approaches.

Opportunity

Antimicrobial susceptibility testing is undergoing a revolution thanks to developments in automation and molecular diagnostic methods. Rapid diagnostic assays that identify genetic markers of drug resistance straight from clinical samples are replacing traditional AST approaches based on culture and phenotypic detection. Resistance can now be detected in a matter of hours rather than days because to technologies like whole genome sequencing, mass spectrometry, polymerase chain reaction (PCR), and DNA microarrays. Simultaneously, completely automated AST systems are decreasing labor and turnaround times, increasing productivity, and standardizing test outcomes.

Market Restraints

One of the main issues with antimicrobial susceptibility testing is the delay that occurs between the definition of clinical breakpoints, the approval of innovative antimicrobial treatments, and the release of these medications onto the Hong Kong antimicrobial susceptibility testing (AST) market. The FDA establishes certain thresholds when drug companies submit applications for new medications that are denied. The absence of clinical breakpoints for some drugs further hinders the adoption of antimicrobial susceptibility solutions. For instance, no clinical cutoffs are known to assess the effectiveness of antifungal treatment for invasive mold infections other than Aspergillus infections.

Automatic antimicrobial laboratory equipment is very expensive and offers the best features and capabilities. Automated AST systems reduce the durations of incubation and detection. Another obstacle facing this industry is the high cost of maintenance for these devices, which come with state-of-the-art software that needs to be updated on a regular basis.

Competitive Landscape for Antimicrobial Susceptibility Testing Market in Hong Kong

Key Players

Recent Developments and Mergers and Acquisitions

In May 2022, the biotechnology business Qualigen Therapeutics, Inc. stated that it was highlighted at BioMed Israel. Qualigen recently entered into definitive agreements to acquire a majority position in NanoSynex Ltd. The goal of NanoSynex's Innovative Technology is to six-fold the turnaround time for antimicrobial susceptibility test findings.

In April 2022, at the 32nd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID 2022)., the healthcare business Copan Diagnostics Inc. showcased its array of completely automated solutions for identification and antimicrobial susceptibility testing (AST) in clinical microbiology. The FDA-approved Colibri, a completely automated specimen workup tool meant to produce bacterial suspensions for AST testing and prepare MALDI-TOF ID targets, was showcased by COPAN.

Healthcare Policies and Regulatory Landscape for Antimicrobial Susceptibility Testing Market in Hong Kong

Antimicrobial Susceptibility Testing in Hong Kong: payment and research

Public hospitals and clinics, run by the Hospital Authority, are heavily subsidised by the government.⁠[1] ClinicalTrials.gov lists 2 studies on Antimicrobial Susceptibility Testing that are recruiting, active or about to start in Hong Kong.⁠[2]

[1] Hospital Authority. Checked 14 Nov 2026.

[2] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Hong Kong. Retrieved 9 Nov 2026.

Policy changes and Reimbursement scenario

AST products and technologies are likely regulated by bodies like the FDA (US), EMA (EU), and other national/regional regulatory authorities. These regulators set guidelines and standards for the development, validation, and commercialization of AST solutions to ensure safety, efficacy, and accuracy. Reimbursement for AST procedures by public and private payers can impact the adoption and utilization of these tests. Favorable reimbursement policies that cover the costs of AST can drive greater uptake, especially in resource-constrained settings.

Many healthcare systems have implemented antimicrobial stewardship programs that promote the appropriate use of antibiotics. AST plays a crucial role in these programs by guiding clinicians on the selection of the most effective antimicrobial therapy.

Policies and regulations around infection prevention and control in healthcare settings can influence the demand for AST to monitor and manage hospital-acquired infections. Governments and regulatory bodies may offer incentives, grants, or other programs to support the research and development of innovative AST technologies.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Antimicrobial Susceptibility Testing right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 9 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Antimicrobial Susceptibility Testing in context

Hong Kong compared

  • People aged 65 and over: 23.7% of people (2025). World: 10.4% of people (2025). 2nd highest of the 18 countries we cover in APAC.[1]

[1] World Bank Open Data, People aged 65 and over (% of people). Retrieved 22 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

What segments does the Antimicrobial Susceptibility Testing market report cover?
The report splits the market by test type (Phenotypic testing, Genotypic testing, Rapid testing), application (Antibacterial tests, Anti-parasitic tests, Antifungal tests, Antiviral tests), end user (Diagnostic laboratories and hospitals, Pharmaceutical and biotechnology companies, Research and academic institutes) and product (Manual AST products, Automated AST instruments, Consumables).
Who are the key players in the Antimicrobial Susceptibility Testing market?
Key players include Thermo Fisher Scientific Inc., Alifax S.r.l., Creative Diagnostics, Resistell AG, Danaher Corporation and BD (Becton, Dickinson), among 18 companies the report profiles.
What is driving the Antimicrobial Susceptibility Testing market?
Over the projected market, it is anticipated that major companies will increasingly employ inorganic development tactics, like product launches, to propel market expansion.
How is healthcare paid for in Hong Kong?
Public hospitals and clinics, run by the Hospital Authority, are heavily subsidised by the government. Source: Hospital Authority. Checked 14 Nov 2026.
How many clinical trials on Antimicrobial Susceptibility Testing are running in Hong Kong?
2 studies are recruiting, active or about to start in Hong Kong, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Hong Kong. Retrieved 9 Nov 2026.
How much research is published on Antimicrobial Susceptibility Testing?
PubMed lists 9,030 papers on Antimicrobial Susceptibility Testing added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 9 Nov 2026.
Back to Catalogue

Related Healthcare Services reports in Hong Kong

See all

Related on antibiotics and diagnostics and lab testing

See the topic